Abstract 2295
Background
The effect of concomitant chronic hepatitis B (CHB) infection on the risk of colorectal liver metastasis (CRLM) has not been definitively elucidated. Many clinicians believe that CHB is “protective” and although previous reports support their presumption, these studies were limited by small sample size, mixed types of chronic hepatitis and heterogeneous therapies.
Methods
To explore this issue, we retrospectively studied 7187 newly diagnosed colorectal cancer (CRC) patients. The definitions and diagnostic procedures of synchronous CRLM (synCRLM) were as per our previous report.
Results
The prevalence of HBsAg+ was 5.12% (364/7111) and HBeAg+ was 1.25% (76/6075). The overall prevalence of synCRLM was 8.72% (627/7187) and was significantly higher in HBsAg+ patients than HBsAg- patients (13.40% vs. 8.54%, P = 0.031). SynCRLM was also more prevalent in HBeAg+ patients compared to HBeAg- patients (19.70% vs. 10.17%, P = 0.031). In univariate logistic regression analysis, HBeAg+ had the highest hazard ratio (HR) [2.947, P < 0.001] and was more than twice that of HBsAg + (HR: 1.435, P = 0.032). In the subsequent multivariate analysis with other significant factors, HBeAg+ was still the strongest predictor of synCRLM (HR: 2.322, P = 0.044), the HR of HBsAg+ was 1.686 (P = 0.024).
Conclusions
This study focuses only on the newly diagnosed synCRLM and eliminates the effect of various adjuvant and neoadjuvant therapy. In our previous study of 4033 CRC patients and contrary to much of the reported literature, HBsAg+ was associated with significantly increased prevalence of CRLM. HBeAg+ also trended toward increased CRLM prevalence but didn’t reach statistical significance. When expanded to 7187 subjects, HBeAg+ is finally proved to be a predictor of CRLM, with a HR much higher than that of HBsAg+. Unlike the minimal chance of HBsAg loss, HBeAg seroconversion and HBV-DNA repression can be achieved in many CHB patients with current anti-viral therapies. In summary, HBeAg+ is a clinical risk factor for CRLM that can be readily identified and addressed. Whether antiviral treatment can decrease the risk of CRLM is definitely worth further study.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Natural Science Fund of China (No.81872400).
Disclosure
L. Zhao: Speaker Bureau / Expert testimony: Bayer; Speaker Bureau / Expert testimony: MSD. J. Cao: Speaker Bureau / Expert testimony: Bayer. All other authors have declared no conflicts of interest.
Resources from the same session
2674 - Multicenter Phase I Trial of Trastuzumab Emtansine (T-DM1) in Combination with Non-Pegylated Liposomal Doxorubicin (NPLD) in HER2[+] Metastatic Breast Cancer (MBC). THELMA Study
Presenter: Elena López-Miranda
Session: Poster Display session 2
Resources:
Abstract
1398 - Phase 1 study of liposomal formulation of eribulin (E7389-LF) in patients (pts) with advanced solid tumors: primary results of dose-escalation part
Presenter: Noboru Yamamoto
Session: Poster Display session 2
Resources:
Abstract
5818 - Polo-like Kinase 1 inhibitor onvansertib synergizes with paclitaxel in breast cancer carrying p53 mutation
Presenter: Antonio Giordano
Session: Poster Display session 2
Resources:
Abstract
5927 - Phase 1b study of heat shock protein 90 inhibitor, onalespib in combination with paclitaxel in patients with advanced, triple negative breast cancer (NCT02474173).
Presenter: Robert Wesolowski
Session: Poster Display session 2
Resources:
Abstract
1695 - Impact of pertuzumab and T-DM1 on prognosis of HER2-positive metastatic breast cancer (MBC) and factors affecting their efficacy: results from the AGMT_MBC-Registry
Presenter: Simon Peter Gampenrieder
Session: Poster Display session 2
Resources:
Abstract
1742 - Clinical profile and outcome of HER2 positive breast cancer patients with brain metastases treated with HER2 targeted therapy: Real world experience.
Presenter: Prabhat Bhargava
Session: Poster Display session 2
Resources:
Abstract
1846 - Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer: results of single arm phase IV COMACHI study
Presenter: Norikazu Masuda
Session: Poster Display session 2
Resources:
Abstract
5385 - Anti HER-2 Therapies and Left Ventricular Dysfunction The Renaissance Study
Presenter: ANDRES DANIELE
Session: Poster Display session 2
Resources:
Abstract
3320 - Safety and efficacy of T-DM1 in 128 patients with advanced HER2+ breast cancer: The Royal Marsden experience.
Presenter: Nicolò Battisti
Session: Poster Display session 2
Resources:
Abstract
4540 - Use of trastuzumab emtansine (T-DM1; K) after pertuzumab + trastuzumab (PH) in patients with HER2-positive metastatic breast cancer (mBC): challenges in assessing effectiveness of treatment sequencing in the real world (RW)
Presenter: Thibaut Sanglier
Session: Poster Display session 2
Resources:
Abstract